The global nerve repair and regeneration market size reached USD 9.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.2 Billion by 2033, exhibiting a growth rate (CAGR) of 9.45% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 9.5 Billion |
Market Forecast in 2033 | USD 22.2 Billion |
Market Growth Rate (2025-2033) | 9.45% |
Nerve repair and regeneration (NRaR) refers to a neural tissue engineering process used for the treatment of a nerve injury. It facilitates the regrowth of new neurons, glial cells, myelin, axons and synapses. It also aids in restoring the normal functioning of the nerve after nerve damage, which is usually caused by pressure, blunt trauma, stretching or cutting of a nerve. NRaR involves the use of biomaterials and various neuro-stimulation and neuromodulation devices. Biomaterials include nerve conduits, nerve protectors, nerve wraps, and nerve connectors. They are used for direct neuropathy, nerve grafting, stem cell therapy and transcutaneous, transcranial magnetic, spinal cord, deep brain, sacral nerve and vagus nerve stimulation.
The increasing prevalence of chronic neurological disorders, such as Alzheimer's, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis and multiple system atrophy, is among the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, and escalating instances of nerve injuries are providing a thrust to the growth of the market. Hospitals, ambulatory surgical centers (ASCs) and other healthcare institutes across the globe are providing novel NRaR solutions for timely diagnosis and treatment of neurological disorders. Additionally, various technological advancements in stem cell therapy and the development of innovative neuromodulation devices, are acting as other growth-inducing factors. Endogenous stem cells are being widely used in neurogenesis, neural repair and exogenous neural stem cell transplantation for effective repair and replacement of damaged tissues in the central nervous system. Other factors, including rising healthcare expenditures of the masses, along with the significant improvements in the medical infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global nerve repair and regeneration market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on surgery, product and end user.
Breakup by Surgery:
Breakup by Product:
Breakup by End User:
Breakup by Region:
The report has also provided a comprehensive analysis of the competitive landscape in the global nerve repair and regeneration market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Surgery, Product, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Alafair Biosciences Inc., AxoGen Inc., Baxter International Inc., Boston Scientific Corporation, Collagen Matrix Inc., Integra Lifesciences Corporation, Medtronic plc, Polyganics BV, Soterix Medical Inc., Stryker Corporation and Synapse Biomedical Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global nerve repair and regeneration market was valued at USD 9.5 Billion in 2024.
We expect the global nerve repair and regeneration market to exhibit a CAGR of 9.45% during 2025-2033.
The increasing prevalence of chronic neurological disorders, such as Alzheimer's, Parkinson's disease, amyotrophic lateral sclerosis, etc., is primarily driving the global nerve repair and regeneration market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective nerve injury treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for nerve repair and regeneration.
Based on the surgery, the global nerve repair and regeneration market can be categorized into direct nerve repair/neurorrhaphy, nerve grafting, stem cell therapy, and neurostimulation and neuromodulation surgeries. Currently, neurostimulation and neuromodulation surgeries account for the majority of the global market share.
Based on the product, the global nerve repair and regeneration market has been segregated into biomaterial and neurostimulation and neuromodulation devices, where neurostimulation and neuromodulation devices currently exhibit a clear dominance in the market.
Based on the end user, the global nerve repair and regeneration market can be bifurcated into hospitals and clinics and ambulatory surgical centers. Currently, hospitals and clinics hold the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global nerve repair and regeneration market include Abbott Laboratories, Alafair Biosciences Inc., AxoGen Inc., Baxter International Inc., Boston Scientific Corporation, Collagen Matrix Inc., Integra Lifesciences Corporation, Medtronic plc, Polyganics BV, Soterix Medical Inc., Stryker Corporation, and Synapse Biomedical Inc.